# Inmagene Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/inmagene-bio

- Industry: Pharmaceuticals
- Headquarters: San Diego, US
- Website: www.inmagenebio.com/
- Total disclosed funding: $122M
- Latest round: Series C (Jun 1, 2021)
- Investors on record: 9

## About

Established in 2019 and based in Shanghai, China, Inmagene is a biopharmaceutical company focused on immunology-related therapeutic areas. The company also established branches in San Diego, Shanghai, Hangzhou and Wuhan. Inmagene Biopharmaceuticals has cooperated with Affibody AB, Kissei, and other enterprises. In December 2024, Inmagene Biopharmaceuticals, a portfolio company of BC Capital, Kunlun VC, Panacea Venture, South China Venture Capital, Vertex Ventures China, Calor Capital, Epiphron Capital, HighLight Capital, Triwise Capital, and VMS Group, agreed to merge with Ikena Oncology, Inc., a portfolio company of Atlas Venture, OrbiMed Advisors, Bristol-Myers Squibb Company, BVF Partners, Cowen Investment Management, Farallon Capital Management, Fidelity Investments, HealthCor Management, Invus, Logos Capital, Omega Funds, Surveyor Capital, Acuta Capital Partners, Adage Capital Management, Vestal Point Capital, Gilead Sciences, Inc., Mission Bay Capital, New Enterprise Associates, OUP (Osage University Partners), Sofinnova Investments, SV Health Investors, Vida Ventures, and now operates under the name ImageneBio, Inc., with a PIPE funding of USD 75 million from Deep Track Capital, Foresite Capital, RTW Investments, BVF Partners, BLUE OWL CREDIT PRIVATE FUND ADVISORS, Omega Funds, and OrbiMed Advisors. The company will be publicly listed on the Nasdaq Global Select Market under the ticker symbol "IMA".

Inmagene team integrates efficient resources worldwide to develop drugs for global patients. The company is building a robust pipeline of over 10 drug candidates. Inmagene also in-licenses products for the Asia markets and, together with its partners, carries out global development activities, including multi-center clinical trials. The products of the company can be used in curing psoriasis, arthritis, ankylosing spondylitis, uveitis, and other diseases.

Izokibep (IMG-020), Inmagene’s most advanced drug candidate, is about to enter the global phase 2 or 3 trials for multiple indications.

The combination plans to utilize the January 2025 funding to advance the clinical development of IMG-007 for atopic dermatitis and other inflammatory indications.

## Funding rounds

- Series C, Jun 1, 2021, $100M — HighLight Capital, VMS Group, South China Venture Capital, Triwise Capital, Panacea Venture, Shanhai Capital, Calor Capital, Epiphron Capital
- Series C, Mar 1, 2021, $1M — Calor Capital
- Series B, Nov 8, 2020, $21M — South China Venture Capital, Vertex Ventures China, Panacea Venture, Shanhai Capital

## Investors

- South China Venture Capital (https://capitalatlas.ai/funds/south-china-venture-capital) — Series B, Series C
- Vertex Ventures China (https://capitalatlas.ai/funds/vertex-ventures-china) — Series B
- Panacea Venture (https://capitalatlas.ai/funds/panacea-venture) — Series B, Series C
- Shanhai Capital (https://capitalatlas.ai/funds/shanhai-capital) — Series B, Series C
- Calor Capital (https://capitalatlas.ai/funds/calor-capital) — Series C
- HighLight Capital (https://capitalatlas.ai/funds/highlight-capital) — Series C
- VMS Group — Series C
- Triwise Capital (https://capitalatlas.ai/funds/triwise-capital) — Series C
- Epiphron Capital — Series C